Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Blood

• Publication date

  1997-08-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD.V90.4.1649.1649_1649_1655PMID 9269785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Matrix degrading metalloproteinases

  2005cited by this paper
• Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells.

  1996cited by this paper
• Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies.

  1996cited by this paper
• Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.

  1996cited by this paper
• Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2.

  1996cited by this paper
• Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma.

  1996cited by this paper
• Myeloma Cells Upregulate Interleukin-6 Secretion in Osteoblastic Cells Through Cell-to-Cell Contact But Downregulate Osteocalcin

  1995cited by this paper
• Inhibition of bone resorption in vitro by selective inhibitors of gelatinase and collagenase.

  1995cited by this paper
• Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor

  1995cited by this paper
• Remodeling MMPIs

  1995cited by this paper
• Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin.

  1995cited by this paper
• T cell gelatinases mediate basement membrane transmigration in vitro.

  1995cited by this paper
• Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells.

  1995cited by this paper
• Matrix metalloproteinase inhibition: a review of anti-tumour activity.

  1995cited by this paper
• The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells

  1995cited by this paper
• Role of cytokines in bone resorption.

  1995cited by this paper
• Gelatinase A activity directly modulates melanoma cell adhesion and spreading.

  1995cited by this paper
• Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis.

  1994cited by this paper
• Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130

  1994cited by this paper
• Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130

  1994cited by this paper
• Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures.

  1994cited by this paper
• A matrix metalloproteinase expressed on the surface of invasive tumour cells

  1994cited by this paper
• Progelatinase A activation during tumor cell invasion.

  1994cited by this paper
• Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression.

  1994cited by this paper
• Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells.

  1994cited by this paper
• Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma.

  1994cited by this paper
• Progelatinase A activation during tumor cell invasion.

  1994cited by this paper
• Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma.

  1993cited by this paper
• Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma

  1993cited by this paper
• Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion.

  1993cited by this paper
• Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6.

  1993cited by this paper
• Structural biochemistry and activation of matrix metalloproteases.

  1993cited by this paper
• Human osteoblasts in culture synthesize collagenase and other matrix metalloproteinases in response to osteotropic hormones and cytokines.

  1992cited by this paper
• The matrix‐degrading metalloproteinases

  1992cited by this paper
• Cytokine network in human multiple myeloma.

  1992cited by this paper
• Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema.

  1992cited by this paper
• Matrix metalloproteinases and their inhibitors in connective tissue remodeling

  1991cited by this paper
• Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression.

  1990cited by this paper
• Structure of the human type IV collagenase gene.

  1990cited by this paper
• Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.

  1990cited by this paper
• Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone.

  1990cited by this paper
• Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6.

  1989cited by this paper
• Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.

  1989cited by this paper
• Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates.

  1980cited by this paper

• Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma

  2023cites this paper
• A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance.

  2022cites this paper
• MT2-MMP is differentially expressed in multiple myeloma cells and mediates their growth and progression.

  2022cites this paper
• Aging-associated immune system changes in multiple myeloma: The dark side of the moon.

  2021cites this paper
• The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma

  2021cites this paper
• The extracellular matrix: A key player in the pathogenesis of hematologic malignancies.

  2020cites this paper
• Vascular and Stromal Contributions to Tumor Bone-Homing: Focus on Multiple Myeloma

  2020cites this paper
• Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma

  2020cites this paper
• Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis

  2020cites this paper
• Treatment of Malignant Gliomas by Therapies Against Matrix Metalloproteinases

  2020cites this paper
• SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma

  2020cites this paper
• Adaptogenic neuronal activity of ficus carica and ubiquinone on neuron-toxicity and oxidative stress in lithium carbonate treated rats

  2019influential citation
• KIM1 and NGAL Expression in Patients with Multiple Myeloma and Clinicopathological Significance

  2019cites this paper
• Angiogenesis and Antiangiogenesis in Multiple Myeloma Angiogenesis and Antiangiogenesis in Multiple Myeloma

  2019cites this paper
• Angiogenesis and Antiangiogenesis in Multiple Myeloma

  2018cites this paper
• IMiDs mediate their anti-myeloma activity via destabilization of the CD147/MCT1 complex

  2018cites this paper
• Investigations into the protective effects of the Multiple Myeloma Bone Marrow Microenvironment

  2018cites this paper
• A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo

  2017cites this paper
• Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall

  2017cites this paper
• Role of Galectins in Multiple Myeloma

  2017influential citation
• Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

  2017cites this paper
• IL-1β, IL-8, and Matrix Metalloproteinases-1, -2, and -10 Are Enriched upon Monocyte–Breast Cancer Cell Cocultivation in a Matrigel-Based Three-Dimensional System

  2017cites this paper
• Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer.

  2017cites this paper
• Matrix metalloproteinases in bone marrow : roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies

  2017cites this paper
• Extracellular matrix and the myeloid‐in‐myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche

  2017cites this paper
• Histone deacetylases meet microRNA-associated MMP-9 expression regulation in glucocorticoid-sensitive and -resistant cell lines.

  2017cites this paper
• Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression

  2017cites this paper
• Endothelial progenitor cells and associated pathways in multiple myeloma

  2016cites this paper
• Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo

  2016cites this paper
• Correlation of Mast Cell Density With Angiogenic Cytokines in Patients With Active Multiple Myeloma.

  2016cites this paper
• Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma

  2016cites this paper
• Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor-κB and upregulation of microRNA-29b.

  2016cites this paper
• Pleiotropic Roles of Metalloproteinases in Hematological Malignancies: an Update.

  2016cites this paper
• Sprouty2 regulates proliferation and survival of multiple myeloma by inhibiting activation of the ERK1/2 pathway in vitro and in vivo.

  2016cites this paper
• Involvement of the arachidonic acid cytochrome P450 epoxygenase pathway in the proliferation and invasion of human multiple myeloma cells

  2016cites this paper
• Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia.

  2016cites this paper
• Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow

  2015cites this paper
• Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells

  2014cites this paper
• Angiogenesis in multiple myeloma.

  2014cites this paper
• Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias

  2014cites this paper
• Emerging Role of Interleukins in Cancer Treatment

  2014cites this paper
• RATIONALE FOR A NOTCH-DIRECTED THERAPY TO PREVENT MULTIPLE MYELOMA CROSSTALK WITH THE OSTEOCLASTOGENIC NICHE

  2014cites this paper
• Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.

  2014cites this paper
• The evaluation of angiogenesis and matrix metalloproteinase-2 secretion in bone marrow of multiple myeloma patients before and after the treatment.

  2013cites this paper
• The role of metalloproteinases im multiple myeloma : implications in the pathogenesis and therapeutics

  2013cites this paper
• Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma.

  2013cites this paper
• NOTCH PRODUCES A DEREGULATION OF CXCR4/SDF-1A CHEMOKINE SIGNALING IN MULTIPLE MYELOMA CELLS

  2013cites this paper
• Migration and Homing in Multiple Myeloma

  2013cites this paper
• The functional significance of the bone marrow microenvironment in multiple myeloma development and progression

  2013cites this paper
• Opposing Functions of Classic and Novel IL-1 Family Members in Gut Health and Disease

  2013cites this paper
• Cytotherapies in multiple myeloma: a complementary approach to current treatments?

  2013cites this paper
• Aspects biologiques de l'angiogenèse dans le myélome multiple

  2013cites this paper
• Accelerates the Growth of Lymphoid Tumors Is Inducible in Lymphoma Cells and Stromelysin-2 (Matrix Metalloproteinase 10)

  2013cites this paper
• Non-Hodgkin's Lymphomas and Tissue Inhibitor of Metalloproteinase (TIMP-1) Expression in Malignant Interleukin-6 Regulation of Matrix Metalloproteinase (MMP-2 and MMP-9)

  2013cites this paper
• Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes

  2013cites this paper
• Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications.

  2013cites this paper
• Apicidin-Resistant HA22T Hepatocellular Carcinoma Cells strongly activated the Wnt/β-Catenin Signaling Pathway and MMP-2 Expression via the IGF-IR/PI3K/Akt Signaling Pathway Enhancing Cell Metastatic Effect

  2013cites this paper
• Università degli Studi di Milano Scuola di Dottorato in Medicina Molecolare

  2012cites this paper
• Emerging strategies for targeting cell adhesion in multiple myeloma.

  2012cites this paper
• The influence of bone marrow stromal cells on matrix metaloproteinases expression in myeloma cell line L 363

  2012influential citation
• Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation

  2012cites this paper
• Cell Trafficking in Multiple Myeloma.

  2012cites this paper
• Multiple myeloma.

  2011cites this paper
• Endothelial activation in experimental metastasis models

  2011cites this paper
• Biological aspects of angiogenesis in multiple myeloma

  2011cites this paper
• Extracellular matrix and angiogenic factors in hematological diseases

  2011cites this paper
• Investigation of the intrinsic mechanism of drug resistance in multiple myeloma

  2011cites this paper
• HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients

  2011cites this paper
• Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells

  2011cites this paper
• Angiogenesis and Multiple Myeloma

  2011cites this paper
• Relationships between MMP-2, MMP-9, TIMP-1 and TIMP-2 levels and their pathogenesis in patients with lupus nephritis

  2010cites this paper
• Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways

  2010cites this paper
• The role of the bone marrow microenvironment in the establishment and progression of multiple myeloma

  2010cites this paper
• Multiple myeloma: biology of the disease.

  2010cites this paper
• Single nucleotide polymorphisms of matrix metalloproteinase 9 (MMP9) and tumor protein 73 (TP73) interact with Epstein-Barr virus in chronic lymphocytic leukemia: results from the European case-control study EpiLymph

  2010cites this paper
• Putting Tumors in Context

  2010cites this paper
• In vitro secretion of matrix metalloprotease 9 is a prognostic marker in childhood acute lymphoblastic leukemia.

  2010cites this paper
• Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis

  2010cites this paper
• The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells.

  2010cites this paper
• Communication between bone marrow niches in normal bone marrow function and during hemopathies progression

  2009cites this paper
• IL‐1α secreted by colon cancer cells enhances angiogenesis: The relationship between IL‐1α release and tumor cells' potential for liver metastasis

  2009cites this paper
• 上皮性異形成および口腔扁平上皮癌におけるIL-1 receptor antagonist (IL-1RA) の発現様相

  2009cites this paper
• A murine model of myeloma that allows genetic manipulation of the host microenvironment

  2009cites this paper
• Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients.

  2008cites this paper
• Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment.

  2008cites this paper
• The role of microenvironment in tumor angiogenesis

  2008cites this paper
• Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase‐9 is not

  2007influential citation
• Up-regulation of matrix metalloproteinase family gene involvement in ursolic acid-induced human lung non-small carcinoma cell apoptosis.

  2007cites this paper
• [Angiogenesis and hematologic malignancy].

  2007cites this paper
• Extravasation and homing mechanisms in multiple myeloma

  2007cites this paper
• The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.

  2007cites this paper
• Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK

  2007cites this paper
• Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.

  2007cites this paper
• Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6.

  2007cites this paper
• Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells

  2007cites this paper
• Role of metalloproteinases MMP‐9 and MT1‐MMP in CXCL12‐promoted myeloma cell invasion across basement membranes

  2006cites this paper
• Bone marrow angiogenesis in multiple myeloma

  2006cites this paper
• Matrix metalloproteinases in bone marrow: roles of gelatinases in physiological hematopoiesis and hematopoietic malignancies.

  2006cites this paper
• Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients

  2006cites this paper
• ARSENIC TRIOXIDE COMPOUND MODULATES MULTIPLE MYELOMA PHENOTYPES: ASSESSMENT ON CELL LINE MODELS

  2006cites this paper